Abstract
Objective To investigate the therapeutic effect of bromocryptine on estrogen-induced pituitary prolactinomas in F344 rats and observe the expression levels of estrogen receptor (ER) ERα,ERβ and dopamine D2 receptor (D2R).Methods Prolactin (PRL),ERα,ERβ and D2 R expressions were detected by immunohistochemistry in pituitary gland.Radioimmunoassay was employed to detect serum PRL level.Results The Serum PRL level of the model group increased significantly compared with the control group,which were (3579.8 -±412.5) μg/L and ( 19.6 ±5.2) μg/L,separately.The serum PRL level ( 110.8 ± 21.3 ) μg/L of the therapeutic group was decreased ( P ＜ 0.01 ).The expression levels of ERα in prolactinomas of the model group and the therapeutic group were higher than the control group; ERβ expression level in the therapeutic group was higher than the other two groups.There were no differences in D2R expressions among the three groups (P ＞ 0.05 ).Conclusion Bromocryptine might have therapeutic effects on estrogen-induced pituitary prolactinoma through inhibiting PRL secretion and tumor growth.ER might play an important role in prolactinomas tumorigenesis and development. Key words: Pituitary prolactinoma; Estrogen; Bromocryptine; Dopamine D2 receptor; Estrogen receptor
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
